Logo

Cepheid Shares Up 8.4 Percent on Anthrax Detection News

Feb 16, 2006

NEW YORK, Feb. 16 (GenomeWeb News) - Shares of Cepheid were up $.80, or 8.41 percent, at $10.31 in afternoon trading after the company this morning said that its GeneXpert real-time PCR platform for mobile anthrax detection had been licensed by biothreat agencies in Oakland, Mich., and Honolulu, Hawaii.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.